Ten pharmaceutical giants join US research initiative

Government researchers will collaborate with 10 large pharmaceutical companies on a $230 million initiative to speed development of new medications for major diseases, the US National Institutes of Health announced Tuesday.

The five-year initiative targets Alzheimer's Disease, , and lupus, and may be expanded to other ailments, the NIH said.

The goal is to pool resources among NIH and the companies, normally vigorous competitors, to enable analysis of large data sets to track disease progression and the effect of therapies.

Data and early-stage research will be shared and made publicly available, and companies are expected to compete on developing commercial drugs once research passes the preliminary phase.

"Currently, we are investing a great deal of money and time in avenues with high failure rates, while patients and their families wait," said NIH Director Francis Collins.

The challenge "is beyond the scope of any one of us and it's time to work together in new ways to increase our collective odds of success," Collins said.

Taking a drug from early discovery through government approval takes over a decade and 95 percent fail the test. That takes the cost of one success to more than $1 billion, NIH said.

The initiative will be overseen by steering committees led by representatives of NIG and the Food and Drug Administraiton, the private sector companies and patient advocacy groups.

"Our most critical health challenges require new, innovative ways to develop medicines and vaccines," said Rupert Vessey, a at Merck, which is joining the initiative.

"Collaborations such as this, that exchange data, share insights and generate knowledge will be important to unravelling the mysteries of the diseases that cause suffering for individuals and a burden to our society."

The other participating companies are: AbbVie, Biogen, Bristol-Myers Squibb, Eli Lilly, GSK, Johnson & Johnson, Pfizer, Sanofi and Takeda.

add to favorites email to friend print save as pdf

Related Stories

Deciphering the DNA of Alzheimer's patients

Dec 04, 2013

(HealthDay)—Data that details every gene in the DNA of 410 people with Alzheimer's disease can now be studied by researchers, the U.S. National Institutes of Health announced this week.

Companies back fast Internet-in-schools initiative

Feb 02, 2014

The White House says it's lined up private support for President Barack Obama's pledge to connect 15,000 schools and 20 million students with high-speed Internet service over the next few years.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

15 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

15 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

16 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

16 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments